Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic
adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an
approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy
in pancreatic adenocarcinoma and provides an update on current studies in the field.
Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.
Rights & PermissionsPrintExport